Value of CD30 detection in the diagnosis and treatment of lymphoma:a multi-center retrospective study
Objective To analyze the current situation of CD30 pathological detection and clinical diagnosis and treatment a-mong 5 hospitals,and to improve the accuracy of clinical diagnosis of lymphoma and effectively guide the application of CD30-directed drugs in clinical practice.Methods This was a multi-center and retrospective study.We collected the clin-ical data of patients diagnosed with lymphoma from 5 real-world Chinese centers from April 7,2012 to May 27,2022 in the form of a survey.Results Among a total of 142 cases,the expression of CD30 of 67 cases of classical Hodgkin lymphoma and 20 cases of anaplastic large-cell lymphoma was qualitatively analyzed,respectively.Additionally,among the remaining 55 cases diagnosed with other types of lymphoma,5 cases were quantitatively and 50 were qualitatively de-scribed.The total number of brentuximab vedotin(BV)users among 142 patients was 23,and the application rate was 16.20％approximately.Nineteen cases out of 23 received BV as the first-line therapy,1 as second-line therapy,1 as third-line and 2 as fourth-line.Patients received a median of 4 cycles(range:2-6)of BV treatment,the median medica-tion duration was 3.3 months(range:0.5-12.0),and the 1-year PFS and OS rates were 86.96％and 95.65％,respec-tively.Eighteen out of 19 patients underwent effectiveness evaluation,including 8 cases of complete response,7 cases of partial response,and the objective response rate was 83.33％.Conclusions There are obvious differences in the detection methods and the interpretation results of CD30 immunohistochemistry among various centers.Additionally,BV is quite effective in treating CD30-positive lymphoma,but more real-word data is still needed.
CD30lymphomaimmunohistochemistrybrentuximab vedotinreal-world study
NETL
NSTL
万方数据
